Cediranib Maleate

别名: AZD2171 maleate 中文名称：西地尼布马来酸盐

目录号：S5242 Purity: 99.93%

Cediranib Maleate (AZD2171) is the maleate salt of Cediranib, which is a potent inhibitor of VEGFR with IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM.

Cediranib Maleate Chemical Structure

CAS: 857036-77-2

规格	价格	库存
10mg	794.51	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次： S524201 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false 纯度： 99.93%

99.93

Cediranib Maleate相关产品

相关靶点	VEGFR1 VEGFR2 VEGFR3	点击展开
相关产品	Cediranib (AZD2171) Vatalanib (PTK787) 2HCl Linifanib (ABT-869) SAR131675 Apatinib Apatinib (YN968D1) mesylate Ki8751 ZM 323881 HCl Semaxanib (SU5416) SU5402 Motesanib Diphosphate (AMG-706) Brivanib (BMS-540215) Motesanib (AMG-706) ZM 306416 KRN 633 Telatinib Fruquintinib SKLB1002 Taxifolin (Dihydroquercetin) BAW2881 (NVP-BAW2881) SU14813 SU1498 SU5614 SKLB 610 Brivanib Alaninate (BMS-582664) SU5408 SU5204	点击展开
相关化合物库	激酶抑制剂库酪氨酸激酶抑制剂分子库 PI3K/Akt 抑制剂库细胞周期化合物库血管生成相关化合物库	点击展开

生物活性

产品描述

Cediranib Maleate (AZD2171) is the maleate salt of Cediranib, which is a potent inhibitor of VEGFR with IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM.

靶点

VEGFR2/KDR ^[2] (HUVECs)	c-Kit ^[2] (HUVECs)	c-Kit ^[2] (HUVECs)	VEGFR3/FLT4 ^[2] (HUVECs)	VEGFR1/FLT1 ^[2] (HUVECs)	点击更多
0.5 nM	2 nM	2 nM	<=3 nM	5 nM	点击更多

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT00458731	Completed	Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK/T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Childhood Burkitt Lymphoma\|Childhood Diffuse Large Cell Lymphoma\|Childhood Grade III Lymphomatoid Granulomatosis\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Progressive Hairy Cell Leukemia Initial Treatment\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Childhood Anaplastic Large Cell Lymphoma\|Stage IV Childhood Hodgkin Lymphoma\|Stage IV Childhood Large Cell Lymphoma\|Stage IV Childhood Lymphoblastic Lymphoma\|Stage IV Childhood Small Noncleaved Cell Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IVA Mycosis Fungoides/Sezary Syndrome\|Stage IVB Mycosis Fungoides/Sezary Syndrome\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Unspecified Childhood Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	May 2007	Phase 1

参考文献
[1] Brave SR, et al. Mol Cancer Ther. 2011, 10(5):861-73. [2] Wedge SR, et al. Cancer Res. 2005, 65(10):4389-400.

参考文献

化学信息&溶解度

分子量	566.58	分子式	C₂₅H₂₇FN₄O₃.C₄H₄O₄
CAS号	857036-77-2	SDF	--
Smiles	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=CC(=O)O)C(=O)O
储存条件(自收到货起)	3年 -20°C 粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年 -20°C 粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 100 mg/mL ( (176.49 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):